Herpes Simplex Virus Impacts Corneal Transplants

This higher failure rate occurred even when herpes simplex virus infection did not appear to be active in patients. Researchers at the Kellogg Eye Center, University of Michigan, theorized that such patients might have corneal inflammation that could not be detected upon clinical examination but might increase the risk of transplant rejection.

To test this theory, a study led by Victor M. Elner, MD, PhD, examined the corneal tissue, removed during surgery, of 62 Kellogg Eye Center patients (between 1990 and 2000) to identify inflammation biomarkers that might be linked to rejection of transplants. Unlike organ transplants, in corneal procedures the new tissue is placed on a bed of existing tissue. Though herpes simplex virus had been inactive for six months before surgery in 81 percent of patients, microscopic evidence of inflammation was found in 74 percent, and the transplant failure rate did indeed correlate with the presence of this biomarker. Testing for inflammatory biomarkers will help Eye M.D.s (ophthalmologists) predict whether an herpes simplex virus patient is likely to reject a transplant.

"It is also possible that treating herpes simplex virus inflammation intensively before corneal transplant surgery would reduce the risk of rejection," said Dr. Roni M. Shtein, MD, MS, cornea specialist and lead author of the report.

By American Academy of Ophthalmology